Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Aqua Bio Technology ASA's Equity-to-Asset or its related term are showing as below:
During the past 13 years, the highest Equity to Asset Ratio of Aqua Bio Technology ASA was 0.87. The lowest was -0.61. And the median was 0.44.
OSTO:ABTO's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.69 * Ranked among companies with meaningful Equity-to-Asset only.
Aqua Bio Technology ASA (OSTO:ABTO) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Aqua Bio Technology ASA Equity-to-Asset Related Terms
Aqua Bio Technology ASA Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ABTO vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Aqua Bio Technology ASA's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aqua Bio Technology ASA Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aqua Bio Technology ASA's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Aqua Bio Technology ASA's Equity-to-Asset falls into.
Aqua Bio Technology ASA Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Aqua Bio Technology ASA's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aqua Bio Technology ASA (OSTO:ABTO) has a Equity-to-Asset of -0.00 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aqua Bio Technology ASA and its competitors. According to the industry distribution chart, Aqua Bio Technology ASA ranks #999999 out of 1414 companies in the Biotechnology industry.
Is Aqua Bio Technology ASA's Equity-to-Asset too high?
Aqua Bio Technology ASA's current Equity-to-Asset is -0.00. Based on the distribution chart, Aqua Bio Technology ASA ranks #999999 out of 1414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aqua Bio Technology ASA has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Aqua Bio Technology ASA's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aqua Bio Technology ASA ranks #999999 out of 1414 companies for Equity-to-Asset. This places Aqua Bio Technology ASA in the lower half of its industry. The industry median Equity-to-Asset is 0.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aqua Bio Technology ASA and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aqua Bio Technology ASA's current Equity-to-Asset is -0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aqua Bio Technology ASA stock overvalued right now?
Aqua Bio Technology ASA (OSTO:ABTO) has a current Equity-to-Asset of -0.00. The stock's GF Value™ is kr4.02, compared to a current price of kr6.82 — trading 69.7% above its estimated fair value. The current Equity-to-Asset is -0.00. Aqua Bio Technology ASA's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Aqua Bio Technology ASA (OSTO:ABTO), the current Equity-to-Asset is -0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aqua Bio Technology ASA (OSTO:ABTO) Overvalued in 2026?
Based on GuruFocus' analysis, Aqua Bio Technology ASA stock appears to be overvalued.
The current stock price of kr6.82 is trading 69.7% above its estimated GF Value™ of kr4.02.
Key valuation signals for OSTO:ABTO:
Equity-to-Asset: -0.00
GF Value™: kr4.02 vs. price of kr6.82 (69.7% above fair value)
No single metric tells the full story. See the OSTO:ABTO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aqua Bio Technology ASA develops, produces and markets active ingredients for the personal care industry. It creates products for personal care, healthcare, and cosmetics with the help of marine biotechnology. ABT's brands include Moana-Organic skin care and Cuvget-Arctic skin care.
39GF Score
Get the complete analysis for OSTO:ABTO
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ABTO has been successfully added to your 
